# AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies

> **NCT02504346** · PHASE2 · UNKNOWN · sponsor: **Oslo University Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Lung Cancer
- Targeted Therapy

## Interventions

- **DRUG:** AZD9291

## Key facts

- **NCT ID:** NCT02504346
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-08
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-06
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02504346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02504346, "AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02504346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*